Alaunos Therapeutics, Inc. (TCRT) - 10-Q Summary for Period Ended June 30, 2025
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder company that has strategically reprioritized away from its historical focus on clinical-stage oncology TCR-T cell therapies. The Company is currently advancing a small molecule oral obesity program while exploring strategic alternatives, including potential mergers, acquisitions, or asset sales. The Company is classified as a "Smaller Reporting Company" and a "Non-Accelerated Filer."
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenue | $2,000 | $6,000 |
| Net Loss | $(2,124,000) | $(2,810,000) |
| Research & Development Expenses | $531,000 | $306,000 |
| General & Administrative Expenses | $1,603,000 | $2,607,000 |
| Cash and Cash Equivalents (End of Period) | $2,879,000 | $2,464,000 |
| Stockholders' Equity | $3,661,000 | $3,771,000 |
| Accumulated Deficit | $(922,570,000) | $(918,577,000) |
Liquidity: As of June 30, 2025, the Company held approximately $2.9 million in cash. Management anticipates these resources will fund operations into the first quarter of 2026. The Company has raised approximately $3.3 million in financing during the six months ended June 30, 2025, including proceeds from a registered direct offering and sales of Series A-1 and A-2 preferred stock.
Material Changes vs. Prior Period
- Revenue Decline: Royalty revenue decreased by 67% year-over-year to $2,000, driven by lower sales of the licensed product darinaparsin in Japan.
- Expense Reduction: General and Administrative (G&A) expenses decreased by 39% ($1.0 million) compared to the prior year, primarily due to reduced employee-related costs, consulting fees, and insurance costs following workforce reductions and operational streamlining.
- R&D Increase: R&D expenses increased by 74% ($225,000) year-over-year. This increase is attributed to regulatory submission costs related to the wind-down of clinical activities and consulting fees for the new obesity program.
- Capital Structure: The Company issued 500 shares of Series A-1 Preferred Stock and 850 shares of Series A-2 Preferred Stock, and conducted a registered direct offering of common stock and pre-funded warrants, significantly increasing cash reserves compared to the prior period.
Outlook, Risks, and Management Commentary
Going Concern: Management has concluded that substantial doubt exists regarding the Company's ability to continue as a going concern. The Company has an accumulated deficit of approximately $922.6 million and requires substantial additional capital to fund operations beyond the first quarter of 2026. If additional financing is not secured, the Company may need to curtail operations or pursue dissolution.
Nasdaq Compliance: The Company received a notice from Nasdaq on April 7, 2025, stating that its stockholders' equity fell below the $2.5 million minimum requirement (reported at $2.1 million in the 2024 10-K). A compliance plan was submitted on May 22, 2025. Failure to regain compliance could result in delisting, which would impair liquidity and the ability to consummate strategic transactions.
Strategic Reprioritization: The Company is actively exploring strategic alternatives, including acquisitions, mergers, or asset sales, to maximize shareholder value. The TCR-T clinical trial was wound down in 2023, and the focus has shifted entirely to the preclinical small molecule obesity program. Initial data from in vitro and in vivo studies for the obesity program is expected no later than Q4 2025.
Internal Controls: The Company identified a material weakness in its internal control over financial reporting, resulting in disclosure controls and procedures being deemed ineffective as of June 30, 2025.
Leadership Changes: Subsequent to the period end, Dale Curtis Hogue, Jr. resigned as CEO and Board member. Holger Weis was appointed CEO and Chair of the Board on July 2, 2025.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the projection that current cash ($2.9M) will last only until Q1 2026 given the burn rate.
- Nasdaq Status: Confirm whether Nasdaq has accepted the compliance plan submitted on May 22, 2025, and the timeline for regaining compliance.
- Financing Terms: Review the specific conversion prices and anti-dilution provisions of the newly issued Series A-1 and A-2 Preferred Stock to assess potential dilution.
- Obesity Program Progress: Monitor the Q4 2025 data release for the small molecule obesity program to validate the strategic pivot.
- Internal Controls: Assess the remediation plan for the identified material weakness in internal controls over financial reporting.